“It’s never too late to retire early”

How a Pfizer cancer drug pact launched this stock into a breakout

How a Pfizer cancer drug pact launched this stock into a breakout
Female Worker in Med Laboratory


Celcuity Inc (NASDAQ: CELC)

Celcuity Inc (NASDAQ: CELC)

Celcuity is a biotech company based in Minneapolis that focuses on cancer treatments. While their stock price has been trending upwards for several months now, it recently skyrocketed due to an exciting new deal with Pfizer.

Pfizer is one of the world’s foremost pharmaceutical companies right now, and they made an exclusive deal with Celcuity for a breast cancer treatment. Since Pfizer is such a respected company, this deal immediately gives Celcuity some clout.



Celcuity is a smaller company with a market capitalization of US$162m, so it may still be flying under the radar of many institutional investors. Hedge funds do not own Celcuity. The company’s CEO Brian Sullivan is the largest shareholder with 22% of shares outstanding. 

Lance Laing, the second-largest shareholder with 10% of shares outstanding, is Top Key Executive, pointing towards strong insider ownership amongst the company’s top shareholders.

Celcuity has had a solid price increase for twelve weeks, gaining 90.7% over this period. Additionally, it’s trading at 89.6% of its 52-week High-Low Range, hinting that it could be on the verge of a breakout.

You do not want to miss this rare event that could make you a fortune

Recommended Link:

It’s Finally Here…

It’s being called, “The Millionaire Maker Event”…
(Clicking automatically opts you in – Privacy Policy)

A brilliant man by the name of Chris Rowe is making a strong prediction…

And it’s important you know about this in time.

Why should you pay attention to Chris Rowe’s latest prediction?
(Clicking automatically opts you in – Privacy Policy)

For one simple reason…

He has one of the best track records in America when it comes to spotting the massive stock market moves before they happen.

Look at this.
(Clicking automatically opts you in – Privacy Policy)

Top headlines you shouldn’t miss

Is today’s stock an asset to your portfolio?

How a Pfizer cancer drug pact launched this stock into a breakout

Two must-own biotech stocks to buy next month

Here are the best biotech stocks to watch this monthFive blue-chip biotech stocks to buy this year

Three bargain stocks to buy right now


It’s never too late to start saving,

Gordon Fox

P.S.

Know someone who’d love the Late Investor? Be sure to send them to this link so they can get signed up: investinglate.com

Gordon Fox
Gordon Fox is the editor of investinglate.com and writes about Investments, Savings, and how to make the most of your money